These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27090817)

  • 1. Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study.
    Hvas CL; Dige A; Bendix M; Wernlund PG; Christensen LA; Dahlerup JF; Agnholt J
    Eur J Clin Invest; 2016 Jun; 46(6):555-63. PubMed ID: 27090817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study.
    Singla V; Pratap Mouli V; Garg SK; Rai T; Choudhury BN; Verma P; Deb R; Tiwari V; Rohatgi S; Dhingra R; Kedia S; Sharma PK; Makharia G; Ahuja V
    J Crohns Colitis; 2014 Mar; 8(3):208-14. PubMed ID: 24011514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
    Probert CS; Dignass AU; Lindgren S; Oudkerk Pool M; Marteau P
    J Crohns Colitis; 2014 Mar; 8(3):200-7. PubMed ID: 24012063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
    Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
    Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
    Fernández-Bañares F; Hinojosa J; Sánchez-Lombraña JL; Navarro E; Martínez-Salmerón JF; García-Pugés A; González-Huix F; Riera J; González-Lara V; Domínguez-Abascal F; Giné JJ; Moles J; Gomollón F; Gassull MA
    Am J Gastroenterol; 1999 Feb; 94(2):427-33. PubMed ID: 10022641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G; Sandborn WJ; Barrett K; Hodgson I; Streck P
    Am J Gastroenterol; 2012 Jul; 107(7):1064-77. PubMed ID: 22565161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
    Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
    Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
    Hanai H; Iida T; Takeuchi K; Watanabe F; Maruyama Y; Andoh A; Tsujikawa T; Fujiyama Y; Mitsuyama K; Sata M; Yamada M; Iwaoka Y; Kanke K; Hiraishi H; Hirayama K; Arai H; Yoshii S; Uchijima M; Nagata T; Koide Y
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1502-6. PubMed ID: 17101300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.
    Zezos P; Patsiaoura K; Nakos A; Mpoumponaris A; Vassiliadis T; Giouleme O; Pitiakoudis M; Kouklakis G; Evgenidis N
    Colorectal Dis; 2014 Dec; 16(12):O420-30. PubMed ID: 25040651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients' self-reported well-being: A randomized double-blind controlled trial.
    Masoodi M; Mahdiabadi MA; Mokhtare M; Agah S; Kashani AHF; Rezadoost AM; Sabzikarian M; Talebi A; Sahebkar A
    J Cell Biochem; 2018 Nov; 119(11):9552-9559. PubMed ID: 30132960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
    Scherl EJ; Pruitt R; Gordon GL; Lamet M; Shaw A; Huang S; Mareya S; Forbes WP
    Am J Gastroenterol; 2009 Jun; 104(6):1452-9. PubMed ID: 19491859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis.
    Fiorino G; Gilardi D; Naccarato P; Sociale OR; Danese S
    Dig Liver Dis; 2014 Apr; 46(4):330-4. PubMed ID: 24462118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
    Sandborn WJ; Regula J; Feagan BG; Belousova E; Jojic N; Lukas M; Yacyshyn B; Krzeski P; Yeh CH; Messer CA; Hanauer SB
    Gastroenterology; 2009 Dec; 137(6):1934-43.e1-3. PubMed ID: 19766640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study.
    Guijarro LG; Mate J; Gisbert JP; Perez-Calle JL; Marin-Jimenez I; Arriaza E; Olleros T; Delgado M; Castillejo MS; Prieto-Merino D; Gonzalez Lara V; Pena AS
    World J Gastroenterol; 2008 May; 14(18):2851-7. PubMed ID: 18473409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis.
    Hartman DS; Tracey DE; Lemos BR; Erlich EC; Burton RE; Keane DM; Patel R; Kim S; Bhol KC; Harris MS; Fox BS
    J Crohns Colitis; 2016 Jun; 10(6):641-9. PubMed ID: 26802087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D; Yarlas A; Hodgkins P; Karlstadt R; Yen L; Kane S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential utility of a new ulcerative colitis segmental endoscopic index combining disease severity and the extent of inflammation.
    Suzuki Y; Uchiyama K; Kato M; Matsuo K; Nakagawa T; Kishikawa H; Kimura N; Kasanuki J; Ino S
    J Clin Gastroenterol; 2015; 49(5):401-6. PubMed ID: 25127112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.